*Staphylococcus lugdunensis* and coagulase-negative staphylococci species characterisation in a tropical climate

Matthew Howes, Rob Baird

Differentiation between coagulase negative staphylococci (CoNS), a heterogeneous group of human and animal colonisers, and their virulent relative Staphylococcus aureus was historically important. In recent times, Staphylococcus lugdunensis has gained special attention in public health as a human pathogen and has been shown to cause severe invasive disease.1 Biochemical and genomic identification has become more widely and routinely available, allowing the CoNS species distribution in human clinical samples to be better defined.2 We characterised the CoNS species from a single tropical tertiary centre for both swab and blood isolates, and review and compare with previous studies.3 This study was ethics approved: EFILE2022/25273.

Geographically, Royal Darwin Hospital is the tertiary referral hospital for the Top End of the Northern Territory, a region of over 500,000 km2 with a tropical climate (latitude 12.5°S). All clinical isolates of CoNS identified from 1 January 2019 to 30 June 2022 were included, with duplicate patient specimens excluded. During this time there were also 7,546 S. aureus isolates (including 161 [2.1%] from bloodstream isolates). Isolates were biochemically identified by Vitek 2 (Biomerieux, St Louis USA) and characterised as blood or swab isolates. There were 1,262 isolates collected, of which 203 (16%) were from bloodstream samples. The results are presented in Table 1.

Table 1: Characterisation of swab and bloodstream isolates of CoNS between 2019 and 2022

|  |  |  |  |
| --- | --- | --- | --- |
| Species | All sites isolates number and frequency N (%) | Blood isolates N (% of total CoNS) | % blood versus all sites isolates |
| *S. epidermidis* | 389 (30.8) | 104 (51.2) | 26.7% |
| *S. lugdunensis* | 201 (15.9) | 1 (0.5) | 0.5% |
| *S. saprophyticus*a | 193 (15.3) | 3 (1.5) | 1.6% |
| *S. haemolyticus* | 184 (14.6) | 28 (13.8) | 15.2% |
| *S. capitis* | 55 (4.4) | 23 (11.3) | 41.8% |
| *S. hom.hominis* | 44 (3.5) | 23 (11.3) | 52.3% |
| *S. caprae* | 38 (3.0) | 4 (2.0) | 10.5% |
| *S. simulans* | 36 (2.9) | 1 (0.5) | 2.8% |
| *S. lentus* | 29 (2.3) | 4 (3) | 13.8% |
| *S. pseudintermedius* | 24 (1.9) | 2 (1.0) | 8.3% |
| *S. sciuri* | 21 (1.7) | 1 (0.5) | 4.8% |
| *S. warneri* | 14 (1.1) | 2 (1.0) | 14.3% |
| *S. auricularis* | 13 (1.0) | 4 (2.0) | 30.8% |
| *S. cohnii cohnii* | 10 (0.8) | 2 (1.0) | 20.0% |
| *S. xylosus* | 4 (0.3) | 0 (0) | 0.0% |
| *S. carn.carnosus* | 3 (0.2) | 0 (0) | 0.0% |
| *S. schleiferi* | 2 (0.2) | 0 (0) | 0.0% |
| *S. gallinarum* | 1 (0.1) | 0 (0) | 0.0% |
| *S. kloosii* | 1 (0.1) | 1 (0.5) | 100.0% |
| **Total** | **1,262 (100)** | **203 (16.1)** |  |

a predominantly urine isolates

S. epidermidis was predominant, accounting for 30.8% of all CoNS isolates and over 50% of the bloodstream isolates; S. saprophyticus was found predominantly in urine; and S. epidermidis-like organisms (S. haemolyticus, S. capitis and S. hominis) were also frequent in swab and bloodstream isolates.

S. lugdunensis was the second most commonly isolated CoNS species identified with 201 isolates, 15.9% of all isolates. This frequency is far higher than in other published series.4 Of the S. lugdunensis isolates, 24.0% and 66.3% came from the pelvic and lower body sites respectively, consistent with previous studies.5

However, despite the large number of skin swab isolates, there was only a single bloodstream isolate of S. lugdunensis detected during this study, from a patient admitted with fever and found to have S. lugdunensis in one blood culture bottle only. Repeat blood cultures were negative three days later. The patient had a presumed ileostomy source and received two weeks of intravenous antibiotics for bacteraemia, and the patient remained well on review.

Though it accounted for 15.9% of all CoNS isolates, S. lugdunensis represented only 0.5% of CoNS bloodstream isolates, with a low 0.5% rate of blood to swab isolates. Our rate of bloodstream S. lugdunensis isolation was much lower than recorded in comparably sized series.2 A further retrospective look back over ten years identified only two other bloodstream isolates, both one bottle only, with neither deemed clinically significant. This low incidence of serious bloodstream infection over ten years has not been reported previously from tropical settings.6

Our study demonstrates that high rates of S. lugdunensis carriage in the tropics does not necessarily translate into invasive disease; this raises the question of whether the tropical environment potentially affects the virulence of the organism. This is something for potential future studies to examine. As a tropical centre, the frequency of isolation of S. lugdunensis raises concerns for potential for significant burden on the health service in line with high rates of S. aureus, particularly methicillin-resistant strains. We plan to sequence a number of local S. lugdunensis isolates to determine the presence of postulated virulence factors, and to compare phylogenetic relationships with known virulent strains, so as to characterise this epidemiological observation.

# Author details

Matthew Howes1
Rob Baird1

1. Territory Pathology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia

## Corresponding author

Matthew Howes

Territory Pathology, Royal Darwin Hospital, Rocklands Tiwi NT 0810 Australia

email: matthewhowes@doctors.org.uk; Matthew.Howes@nt.gov.au

# References

1. Fernández-Fernández R, Lozano C, Ruiz-Ripa L, Robredo B, Azcona-Gutiérrez JM, Alonso CA et al. Antimicrobial resistance and antimicrobial activity of Staphylococcus lugdunensis obtained from two Spanish hospitals. Microorganisms. 2022;10(8):1480. doi: https://doi.org/10.3390/microorganisms10081480.
2. Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014;27(4):870–926. doi: https://doi.org/10.1128/CMR.00109-13.
3. Becker K, Both A, Weißelberg S, Heilmann C, Rohde H. Emergence of coagulase-negative staphylococci. Expert Rev Anti Infect Ther. 2020;18(4):349–66. doi: https://doi.org/10.1080/14787210.2020.1730813.
4. Frank KL, Del Pozo JL, Patel R. From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis. Clin Microbiol Rev. 2008;21(1):111–33. doi: https://doi.org/10.1128/CMR.00036-07.
5. Kleiner E, Monk AB, Archer GL, Forbes BA. Clinical significance of Staphylococcus lugdunensis isolated from routine cultures. Clin Infect Dis. 2010;51(7):801–3. doi: https://doi.org/10.1086/656280.
6. Parthasarathy S, Shah S, Raja Sager A, Rangan A, Durugu S. Staphylococcus lugdunensis: review of epidemiology, complications, and treatment. Cureus. 2020;12(6):e8801. doi: https://doi.org/10.7759/cureus.8801.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection and Response, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Noel Lally

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

**Website**: <http://www.health.gov.au/cdi>

**Contacts**CDI is produced by the Office of Health Protection and Response, Australian Government Department of Health and Aged Care, GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** cdi.editor@health.gov.au

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: cdi.editor@health.gov.au.

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2022 Commonwealth of Australia as represented by the Department of Health and Aged Care

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health and Aged Care, GPO Box 9848, Canberra ACT 2601, or via e-mail to: copyright@health.gov.au

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.
<http://www.health.gov.au/cdna>